Linking Biochemical Pathways and Networks to Adverse Drug Reactions by Zheng, Huiru et al.




Abstract—There is growing interest in investigating the 
biochemical pathways involved in cellular responses to drugs. 
Here we propose new methods to explore the relationships 
between drugs, biochemical pathways and adverse drug reactions 
(ADRs) at a large scale. Using sparse canonical correlation 
analysis of 832 drugs characterized by 173 pathways and 1385 
ADRs profiles, we identified 30 highly correlated sets of drugs, 
pathways and ADRs. This included known and potentially novel 
associations. To evaluate the predictive performance of our 
method, the extracted correlated components were used to 
predict known ADR profiles from drug pathway profiles. A 
relatively high prediction performance (AUC: 0.894) was 
achieved. To further investigate their association, we developed a 
network-based approach to extract potentially significant 
modules of pathway-ADR associations. Five statistically 
significant modules were extracted. We found that most of the 
nodes contained in the modules are either pathways linked to a 
very limited number of drugs or rare ADRs. The work provides a 
foundation for future investigations of ADRs in the context of 
biochemical pathways under different clinical conditions. Our 
method and resulting datasets will aid in: a. the systematic 
prediction of ADRs, and b. the characterization of novel 
mechanisms of action for existing drugs. This merits additional 
research to further assess its potential in improving personalised 
drug safety monitoring, as well as for the repositioning of drugs 
in the longer-term 
 
Index Terms— Biological pathways; adverse drug reactions;  
sparse canonical correlation analysis, pharmacogenetics 
I. INTRODUCTION 
ccording to the World Health Organisation [1], an 
adverse drug reaction (ADR) is defined as “a response to 
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a drug which is noxious and unintended, and which occurs at 
doses used in humans for the prophylaxis, diagnosis or therapy 
of disease, or for the modification of physiological function”. 
It has been well recognised that ADRs are a significant cause 
of morbidity and mortality, resulting in a significant burden on 
the healthcare service across the world [2], [3]. For example, it 
has been estimated that ADRs would account for 6.5% of all 
UK hospital admissions, which costs the National Health 
Service (NHS) up to £466 million annually [4]. Thus, during 
early phases of drug development, identification of potential 
ADRs is critical for successful drug development. 
The recognised significance has triggered huge efforts from 
industry and scientific communities to develop various 
computational models for predict potential ADRs at large 
scale. Bender et al. [5] explored the chemical space and made 
the first attempt to predict ADRs across hundreds of ADR 
categories from chemical structure alone, achieving 92% 
classification accuracy. Cami et al. [6] developed a 
computational network-based method for predicting ADRs. 
They constructed a network representation of the associations 
between drugs and adverse drug events (ADE) using 809 
drugs and 852 ADEs collected since 2005, and then trained a 
logistic regression model to predict unknown side effects of 
drugs in the network. Liu et al. [7] proposed a machine-
learning-based approach for ADR prediction by integrating 
chemical structure information, drug related biological 
properties, such as protein targets and pathway information, 
and drug phenotypic characteristics. They found that drug 
phenotypic information such as the drug indication is the most 
informative feature of ADR prediction. The model 
successfully predicted the ADRs that are associated with the 
withdrawal of rofecoxib and cerivastatin. More recently, 
Harpaz et al. [8] proposed a “signal-detection strategy” that 
combines the adverse event reporting system (AERS) of the 
USA Food and Drug Administration (FDA) and electronic 
health records (EHRs) for detection of ADRs. Finally, Lui et 
al. [9] proposed a causality analysis model based on structure 
learning to identify important factors that contribute 
significantly to specific drug ADRs. After applying the causal 
features captured by the proposed model to a traditional 
support vector machine classifier, a significant increase in 
performance was reported 
We have entered big data era. There are massive amounts of 
pharmacogenetic and related data already available, and 
growth rate of such data is expected to be even higher in the 
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next few years. Therefore, it is important for us to identify 
important molecular signals underlying the pharmacogenetic 
data. Specifically, it is promising to investigate biochemical 
pathways involved in cellular response to drugs because drug 
targets are often involved in important pathways. Wallach et 
al. [10] highlighted that understanding the biological processes 
behind the occurrence of ADRs may have significant 
applications and implications in the life sciences and 
pharmaceutical industries. This may lead to the development 
of safer and more effective drugs, the discovery of new bio-
markers, and the identification of new uses for existing drugs 
(drug repositioning). Silberberg et al. [11] argued that 
uncovering drug-induced signaling pathways is an important 
step in understanding a drugs’ mode of action and inferring 
drug properties such as ADRs. In an integrative analysis using 
human protein-protein and protein-DNA interactions, as well 
as drug targets and drug-induced gene expression data, they 
identified 428 drug-specific signalling sub-networks and 99 
putative signalling pathways. In another study by Chen et al. 
[12], the authors hypothesized that a portion of a pathway (i.e., 
a sub-graph of the pathway) might be more sensitive in drug 
response to a particular biological condition than the whole 
pathway. This hypothesis is valid because canonical pathways, 
like those annotated in the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) database [13], might be too large and 
complicated while only subpart(s) of a pathway are under 
regulation in a cellular condition or in the response to 
environmental changes. Correspondingly, Chen et al. 
developed a computational framework for searching primary 
subnetwork(s) of drug responses by effectively utilizing the 
sub-pathway information. 
By extending our preliminary analysis [14], here, we further 
investigated the relationship between biochemical pathways 
and ADRs at a large scale using computational approaches. 
Through our computational analyses, we aimed to answer the 
following questions:  (1) Can we identify correlated sets of 
pathways and ADRs by a computational approach? (2) Can we 
predict a drugs’ ADR based on its pathway activity profiles? 
And (3) How to effectively measure the association between 
pathways and ADRs using the data from knowledge base? 
The rest of this paper is organized as follows. Section II 
briefly describes the method, including the datasets and 
prediction algorithms. The results are presented in Section III. 
The discussion and conclusions, together with future research 
directions, are given in Section IV.  
II. METHODOLOGY 
A. Datasets 
The dataset was obtained from a study by Liu et al. [7]. It 
contains 832 drugs, and each drug was represented by the 
following two high-dimensional profiles. 
1) A 1385 binary vector whose elements encode for the 
presence or absence of an ADR by “1” or “0”, respectively. 
The associations between drugs and ADRs were extracted 
from SIDER [16]. 
2) A 173 binary vector in which “1” indicates the 
association between a drug and a corresponding pathway. The 
relationship between drugs and pathways was constructed by 
mapping protein targets extracted from DrugBank [17] to the 
corresponding KEGG biological pathways [18], [19] through 
their protein-coding gene symbols.  
In total, 2182 links between 832 drugs and 173 KEGG 
pathways and 59,205 associations between the drugs and 1385 
ADRs were identified. While each drug has a relatively large 
number of ADRs with a mean of 42.7 and a standard deviation 
of 87.0, the number of pathways linked to each drug is 
relatively small (12.6 on average with a standard deviation of 
22.2). Among them, the drug arsenic trioxide was found to be 
associated with the largest number of pathways (51) derived 
from its protein targets, and pregabalin was found to have the 
largest number of ADRs (453) 
B. Canonical correlation analysis 
Developed by H. Hotelling [20], canonical correlation 
analysis (CCA) aims to quantify the associations among two 
sets of features (pathways and ADR in our case) on the same 
set of samples, i.e. drugs in this study. It has become a well-
known tool in statistical analysis and has attracted growing 
attention over the past years [21], [23] .  
Let each drug be represented by a pathway feature vector 
              
  and an ADR feature vector   
            
  where p and q stand for the number of 
pathways and ADRs under study respectively. Ordinary CCA 
(OCCA) seeks to find two weight vectors α and β for x and y, 
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, where n is the total number of drugs under consideration. 
       and       are called canonical components 
(CCs). In the matrix form, the above optimization problem can 
be rewritten as follows: 
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(2) 
, where               
  and               
  
denote the      and      matrices, respectively. 
It has been shown that normally vectors u and v derived 
from OCCA are not sparse, making the interpretation of 
results quite difficult. In an attempt to impose the sparsity on 
weight vectors α and β to yield interpretable factors, we 
applied the sparse version of CCA (SCCA) based on a 
penalized matrix decomposition (PMD) technique introduced 
by Witten et al. [21]. The idea is to impose additional 
constraints to the elements of α and β, i.e.  
 
                      subject to 
‖ ‖ 
       ‖ ‖ 
      ( )       ( )     
(3) 
 
, where    (     and    (     are parameters used to 
control the sparsity. P1 and P2 are convex penalty functions, 
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which can take on a variety of forms [21]. In this study, the 
SCCA was implemented using (the R package) PMA [22]. A 
lasso penalty was used to obtain the corresponding CCs.  
In order to obtain multiple CCs, a deflation manipulation 
was carried out recursively. The criterion expressed in (3) was 
implemented repeatedly each time by using the       
matrix as the residuals obtained by subtracting the previous 
found factors from the matrix. As a result, m pairs of weight 
vectors, in which high scoring in both sets are extracted as 
correlated sets, will be obtained. The reader is referred to [21] 
and [23] for a detailed description of the implementation. 
III. RESULTS 
A. Associations between ADRs and pathways: a statistical 
analysis 
There is no direct link between the number of linked pathways 
and the number of associated ADRs for each drug as shown in 
Fig. 1 with the Pearson correlation coefficient being close to 
zero (0.074). For example, the drug pregabalin, a drug used 
for neuropathic pain, has the largest number of ADRs (453). 
However, its protein targets were mapped only to 2 KEGG 
pathways (hsa04614 and hsa01040). Interestingly, there is no 
KEGG pathway found to be associated with the drug 
venlafaxine, a drug used for the treatment of major depressive 
disorder, yet it has 319 ADRs. The number of associated 
ADRs for the top 10 drugs that have the largest number of 
pathways varies substantially, ranging from 19 to 244. These 
results highlight the limited amount of available knowledge 
about mechanism of action of clinically approved drugs. 
 
Fig. 1 The correlation between the number of pathways linked to each drug 
and the number of ADRs. 
 
B. Associations between ADRs and pathways: SCCA-based 
analysis 
In order to extract correlated sets of pathways and ADRs, we 
applied SCCA to the dataset. We then evaluated the predictive 
performance of the method by recovering known ADRs from 
the extracted drug pathway profiles. The system was 
implemented within the R framework [24]. The best 
performance was achieved with           and    .  
1) Extraction of KEGG pathway-ADR associations: The 
SCCA-based analysis provides us with 30 CCs, each 
containing a limited number of correlated, high scoring 
pathways and ADRs. To gain a global view of pathway-ADR 
associations, we merged the results for all derived components 
and represented them as a network, in which pathways and 
ADRs are connected if they are found in the same component  
(Fig.2). For simplicity of visulisation, we focused on pathways 
and ADRs whose weights are greater than 0.1. Accordingly, 
this network has a total of 353 nodes, including 296 ADRs and 
57 pathways, and 755 connections. 
 
Fig. 2 An illustration of the network of pathways and ADRs using the 
extracted 30 CCs. Pathways (light grey rectangles) and ADRs (dark circles) 
are connected if they are found in the same extracted CC 
 
The network shows a modular structure, where links 
between ADR and pathway nodes are much denser within 
each CC than between CCs. While CC14, CC21, and CC22 
share the same set of pathways, i.e. taste transduction 
(hsa04742) and type II diabetes mellitus (hsa04930), the 
ADRs having a high score in these three components are very 
different with those having a distinct set of ADRs (11 in 
CC14, 16 in CC21 and 17 in CC22). A similar observation can 
be made when examining the association between pathways 
and ADRs in CC10 and CC13, in which the same pathways, 
i.e. oocyte meiosis (hsa04114) and progesterone-mediated 
oocyte maturation (hsa04914), were found. 
A closer look at the degree distribution reveals that the 
distribution over ADR and pathway nodes is different. All the 
pathways are associated with at least 8 ADRs while other 
pathways: taste transduction (hsa04742) and type II diabetes 
mellitus (hsa04930) are connected to the largest number of 
ADR (41). On the other hand, more than 70% of ADRs are 
connected to less than 3 pathways. Out of 296 ADRs, only 17 
are found to be associated with more than 5 pathways with the 
ADR parapsoriasis (C0030491) linked to the highest number 
of pathways (11). 
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For each component, the associated canonical correlation 
coefficient was estimated. We observed that the components 
with high correlation tend to contain pathways related to very 
few drugs and rare ADRs mainly observed in these drugs. For 
example, CC9 has a highest canonical correlaction close to 1.0 
(0.985). The only pathway found in this component with a 
score greater than 0.1 is proteasome pathway (hsa03050), 
which is only related to bortezomib, the first therapeutic 
proteasome inhibitor to be tested in humans. Intererstingly, all 
14 ADRs contained in the components with a score higher 
than 0.1 are associated with this drug. They are : C0004030, 
C0015544, C0018775, C0032768, C0025309, C0155773, 
C0019357, C0040558, C0002726, C0235329, C0259749, 
C0155919, C0162323, and C0085077. The top pathway found 
in CC6 with the canonical correlation 0.942 is inositol 
phosphate metabolism (hsa00562). The only drug whose 
target protein  is mapped to this pathway is lithium, which 
affects the flow of sodium through nerve and muscle cells in 
the body. The top two ADRs, i.e. nontoxic goiter (C0221777) 
and toxic goiter (C0600086) contained in this component are 
found to be associated with this drug only.  
Our analyses provide two lists of drugs for each extracted 
component: those with a high score for the associated 
pathways and ADRs respectively. Interestingly, most drugs 
that have high scores for pathways in a component with a high 
correlation are found to have high scores for the ADRs in the 
same component. This is consistent with the idea that, in 
principle, the more we know about the mechanism of action of 
a drug, the more we can know about its potential adverse 
effects. For example, the drug lithium has the highest scores 
for both the pathways and ADRs contained in CC6. 
 
2) Performance evaluation: We tested the assumption 
that the extracted correlated sets are predictive of ADRs. To 
do this, we evaluated the performance of the method by using 
the extracted CCs and drug pathway profiles to detect known 
ADR profiles extracted from the SIDER database [16]. 
A 5-fold cross-validation was applied, i.e., the entire 
dataset is randomly partitioned into 5 subsets of approximately 
equal size and each subset in turn is used as the test set while 
the remaining 4 subsets are used as training data. The goal of 
the classification posed in this application is to predict ADRs 
associated with each drug based on its pathway information. 
The performance was assessed by a receiver operating 
characteristics (ROC) curve, which is a plot of  true positive 
rate (the percentage of actual positives correctly identified) 
against  false positive rate (the fraction of false positives out of 
the negatives) at various prediction score thresholds. Any 
predicted ADR with a prediction score greater than a given 
threshold is considered as positive and negative otherwise. 
The area under the ROC curve (AUC) was estimated to 
summarize the prediction performance, as illustrated in Fig.3, 
where the prediction scores for all the ADRs were merged and 
a global ROC curve was obtained. Afterwards, we estimated 
the performance by changing the sparsity parameter, i.e. c1 
and c2, from 0 to 1 with 0.1 increments and the number of CC 
from 10 to 100 with 10 increments. The optimal performance 
was derived with           and    . Both SCCA and 
OCCA achieved fairly good results with SCCA having a 
slightly better performance (AUC: 0.894 for SCCA and 0.888 
for OCCA, well above the performance based on random 
assignment). This suggests that the extracted pathway-ADR 
associations are indeed useful for drug ADR prediction. In 
comparisons with other studies, the results derived from our 
method are at a competitive level with models based on 
chemical and biological features [7], [26]. 
 
Fig. 3 ROC curves based on a 5-fold cross validation. Comparison of the 
performance between SCCA, OCCA, and random 
 
The predictive power of the proposed method can be 
further demonstrated by examining the prediction accuracy of 
the predicted ADRs for each drug. We checked the predicted 
ADRs with high prediction scores against the known ADRs 
reported in the SIDER database [16]Error! Reference source 
not found.. For example, for the drug pramipexole, the ADR 
ranked highest in the prediction score is nasal polyps 
(C0027430), a known ADR for pramipexole [16]. Among the 
top 10 high scoring ADRs, 6 are the known ADRs linked to 
pramipexole. Similarly, the top predicted ADR for the drug 
ropinirole is one of the known ADRs listed in the SIDER 
database, and 9 out of top 15 ADRs with high prediction 
scores are known ADRs for this drug [16]. 
Turning to biological interpretability, we found that the 
proposed SCCA method has the advantage over other machine 
learning techniques, such as Support Vector Machine and 
Naïve Bayesian, which do not provide direct biological 
interpretation clues. As shown in Fig. 4, each correlated set 
derived by SCCA has only a few dominant elements whose 
weight is far greater than the average. Most of the elements in 
the weight vectors associated with each component are zero or 
close to zero in each component, suggesting that SCCA has 
the ability to select a small number of features as informative 
pathway and ADRs. In contrast, almost all elements contained 
in the weight vectors derived from OCCA are non-zero and 
there is no clear dominant element found in most of 
components. Interpreting such a weight vector may prove to 
be rather difficult in practice. 
C. Associations between ADRs and pathways: Network-
based analysis 
In this section we explore the feasibility of using a 
network-based approach to extract associations between 
pathways and ADRs. We first estimated the similarity between 
a pathway and an ADR in terms of their drug profiles. Let a 
pathway, pi, be represented by a binary vector in which each 
> TNB-00034-2014 < 
 
5 
element indicates that the corresponding drug is known to 
impact the pathway or not, i.e.                 (  
         ). 
 
   {
                                            
                                                                            
 (4) 
 
Fig. 4 The distribution of weight vectors over pathways in (a) OCCA and (b) 
SCCA. The first ten canonical components are shown. 
 
Similarly, let an ADR, i.e., sj, be represented by a binary 
vector whose elements encode whether the ADR is associated 
with the corresponding drug,                 (  
         ). 
 
   {
                                           
                                                                     
 (5) 
 
The association between pathway, pi, and ADR,   , can be 
estimated using the Jaccard similarity coefficient, i.e. 
   (     )  
|     |
|     |
 (6) 
The values generated by (6) vary between 0 and 1 where 
“1” implies that the ADR is associated with the same set of 
drugs that impact the given pathway. 
We then constructed a pathway-ADR network, in which the 
edge between pathway and ADR nodes is represented by the 
Jaccard similarity estimated using Equation (6) as shown in 
Fig. 5. Unlike the unweighted network depicted in Fig. 2, in 
which a pathway and a ADR is connected if they are found in 
the same extracted CC, the weighted network illustrated in 
Fig. 5 is based on the proportion of drugs associated with both 
the ADR and the pathway. For a better visualization, here we 
focused on the analysis of the association with the similarity 
greater than 0.1. The resulting network including 724 nodes 
(160 pathways and 564 ADRs) and 1744 weighted edges is 
characterized by a small number of nodes having a high 
degree accompanied by a large number of nodes whose degree 
is less than 3 as depicted in Fig. 5. The top 10 most connected 
nodes are all pathway nodes and the top 3, i.e. gap junction 
(hsa04540), calcium signaling pathway (hsa04020), 
neuroactive ligand-receptor interaction (hsa04080) connect to 
more than 100 ADRs. Interestingly, the cell adhesion 
molecules pathway (hsa04514) is associated with only 2 
drugs, i.e. glatiramer acetate used to treat multiple sclerosis 
and lenalidomide used to treat patient with myeloma yet it 
connects to 33 ADRs, suggesting that these two drugs may in 
reality have a large number of ADRs. The actual numbers of 
known ADRs associated with these 2 drugs are 234 and 234 
respectively. A similar observation can be made when we 
examine the Proteasome pathway (hsa03050), which is only 
linked to one drug (bortezomib) but it has connections with 22 
ADRs.  
The most connected ADR node is C0085786, i.e. alveolitis 
fibrosing, while nearly of ADR nodes are connected to less 
than 3 pathways. Unlike pathway nodes whose degree is 
strongly correlated with the number of associated drugs 
(Pearson correlation coefficient: 0.828), there is virtually no 
correlation between the degree and the number of associated 
drugs for ADR nodes (Pearson correlation coefficient: 
0.0337). For example the ADR C0027497, i.e.nausea, is 
observed in more than 700 drugs, while it is found to link to 4 
pathways, i.e. gap junction (hsa04540), neuroactive ligand-
receptor interaction (hsa04080), calcium signaling pathway 
(hsa04020) and salivary secretion (hsa04970).  
 
Fig. 5 An illustration of a pathway-ADR network, in which the weighted 
edges between pathway and ADR nodes reflect the proportion of drugs 
associated with both the ADR and the pathway estimated using Equation (6). 
 
Next we applied a recently published network clustering 
algorithm, ClusterOne [27], to extract potentially significant 
modules of pathway-ADR associations. A total of 5 modules 
were identified (p < 0.01) as shown in Fig. 6. The p-value was 
established by using a one-sided Mann-Whitney U test 
performed on the in-weights (The sum of the weights of all the 
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edges both of whose endpoints lie in the cluster) and out-
weights (The sum of the weights of the edges having one 
endpoint in the cluster and the other outside) of the vertices 
[27]. A closer look at these modules reveals that most of nodes 
contained are either pathways linked to a very limited number 
of drugs or rare ADRs. For example, the pathway proteasome 
(hsa03050) in Module 1 is found to be only connected to one 
small molecule drug, i.e. bortezomib, which is the first 
proteasome inhibitor to be approved for the treatment of 
relapsed multiple myeloma and mantle cell lymphoma. All the 
other nodes in Module 1 are rare ADRs, which are observed in 
less than 3 drugs including bortezomib. They are aspergillosis 
(C0004030), toxoplasmosis (C0040558), hearing loss bilateral 
(C0018775), keratitis herpetic (C0019357), 
meningoencephalitis (C0025309), failure to thrive 
(C0015544), portal vein thrombosis (C0155773), and post 
herpetic neuralgia (C0032768). Another example is Module 4 
which consists of 6 pathways and 10 ADRs. The average 
number of drugs associated with these nodes is 3.25. The 
ADR benign neoplasm of skin (C0004998) is linked to the 
largest number of drugs (10). The top 2 drugs shared by these 
nodes, i.e. glatiramer acetate (ATC code: L03AX13) and 
thalidomide (ATC code: L04AX02) belong to antineoplastic 
and immunomodulating agents. The drug glatiramer acetate 
used for reduced frequency of relapses in relapsing-remitting 
multiple sclerosis interacts with all 6 pathways, i.e. intestinal 
immune network for IgA production (hsa04672), type I 
diabetes mellitus (hsa04940), asthma (hsa05310), allograft 
rejection (hsa05330), graft-versus-host disease (hsa05332), 
and autoimmune thyroid disease (hsa05320) and has 4 ADRs 
listed in the module, i.e. benign neoplasm of skin (C0004998), 
systolic murmur (C0232257), xanthoma (C0302314), and 
Cervix carcinoma stage 0 (C0851140). The small molecule 
drug thalidomide used for a number of immunological and 
inflammatory disorders is linked to 4 pathways, i.e. type I 
diabetes mellitus (hsa04940), asthma (hsa05310), allograft 
rejection (hsa05330), and graft-versus-host disease (hsa05332) 
and has 6 ADRs contained in the module, i.e. benign neoplasm 
of skin (C0004998), causalgia (C0007462), uterine cervical 
erosion (C0007869), chronic myeloid leukaemia (C0023473), 
lichen unspecified (C0023643), phocomelia (C0031575) and 
microcytic anaemia (C0085576).  
The nodes in Module 3 are linked to more than 25 drugs on 
an average with the ADR hyperkalaemia (C0020461) being 
observed in more than 90 drugs. However, the proportion of 
drugs shared by at least two nodes in this module is relatively 
high. For example, out of 13 drugs found to have the ADR 
pemphigus (an autoimmune blistering skin disorder, 
C0030807), 10 are linked to all 3 pathways in the module, i.e. 
hypertrophic cardiomyopathy (hsa05410), chagas disease 
(hsa05142), and renin-angiotensin system (hsa04614). 
Interestingly, these drugs act on the cardiovascular system and 
are annotated with the same Anatomical Therapeutic Chemical 
Classification (ATC) code at the third level, i.e. C09AA (ACE 
inhibitors). A similar pattern was observed when examining 
the drugs shared by the ADR  hyperkalaemia (C0020461) and 
the three pathways. Despite that a wide range of ATC codes 
are used to annotate the 92 drugs having the ADR 
hyperkalaemia (C0020461), the ATC codes for the drug set 
shared by C0020461 (hyperkalaemia), hsa05410 (hypertrophic 
cardiomyopathy), hsa05142 (chagas disease), and hsa04614 
(renin-angiotensin system)  are exactly the same at the first 3 
levels, i.e. (ACE inhibitors). 
 
 
Fig. 6 Five statistically significant modules identified by ClusterOne. 
Rectangle nodes denote biochemical pathways and circle nodes represent 
ADRs. The p-values associated with each module are 0.002, 0.0001, 0.001, 
0.004, and 0.000004 respectively.   
IV. CONCLUSION 
This investigation proposes a new method to study the 
relationship between biochemical pathways and ADRs at a 
large scale. Using sparse canonical correlation analysis of 832 
drugs with two profiles for 173 pathways and 1385 ADRs, a 
total of 30 correlated sets of pathways and ADRs were 
extracted. To evaluate the performance of the method, the 
extracted correlated components were used to identify known 
ADR profiles from drug pathway profiles using a 5-fold cross 
validation. A relatively high prediction performance (AUC: 
0.894) was achieved. To have a global view of pathway-ADR 
associations, we represented all the components through a 
network, in which pathways and ADRs are connected if they 
are found in the same correlated set.  We found that nearly 
half of ADRs were associated with only a few biochemical 
pathways. To further investigate the association between 
pathways and ADRs, we developed a network-based 
approach, in which the association between a pathway and an 
ADR was estimated by using the Jaccard similarity 
coefficient.  A network consisting of 160 pathways, 564 ADRs 
and 1744 weighted edges was constructed and 5 statistically 
significant modules were extracted. We found that most of the 
nodes contained in the modules are either pathways linked to a 
very limited number of drugs or rare ADRs. At one level, this 
corroborates the limitations of available knowledge about 
ADRs and drug action mechanisms. But it also highlights the 
opportunities for improving such knowledge through 
systematic, network-based prediction approaches. 
To assess global prediction performance across all ADRs, 
we followed the approach adopted by Pauwels et al. [26], i.e. 
> TNB-00034-2014 < 
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drawing a global ROC based on combining the prediction 
scores for all ADRs. It is worth noting that some ADRs are 
observed in only a few drugs. For example, it has been 
observed that the ADR acanthosis nigricans (C0000889) is 
only associated with one drug in the dataset, i.e. nicotinic acid 
used to treat high levels of cholesterol and triglycerides. The 
resulting imbalanced dataset may have a significant impact on 
the estimation of the prediction performance, which would be 
an important part of our future research. Another limitation of 
our study is the constrained sample of drug-pathway 
associations, which is typically based on the notion of single 
drug-single target relationships. However, the resulting 
pathway-centric models go beyond this classical notion of 
drug-induced perturbation, and can expand our view of drug-
target interactions. We will further explore the drug-pathway 
associations in a dynamic cellular systems, though such data is 
currently still a limitation. In comparison to other 
computational approaches such as support vector machines 
and k-nearest neighbours [7], the SCCA-based approach used 
in this study has a clear advantage in terms of interpretability 
of results [26]. Nevertheless, the comparison with other 
related methods, such as those introduced in [5], and the 
examination of the potential clinical implications of novel 
extracted associations between KEGG pathways and ADRs 
deserve further investigation. One possible approach to 
investigate this in a prospective way is to build prediction 
models based on information available until a particular year, 
EndYear, followed by an independent validation on data 
generated after EndYear. 
In summary, our method and resulting datasets will aid in: 
a) the systematic prediction of ADRs, and b) the 
characterization of novel mechanisms of action for existing 
drugs. The predictions that our method generate are both 
testable and biologically interpretable. We believe that the 
combination of these advantages into a single prediction 
strategy opens new research opportunities for improving 
personalised drug safety monitoring, as well as for the 
repositioning of drugs in the long-term.  
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